Company / R&D Expense
MARAVAI LIFESCIENCES HOLDINGS, INC. R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$17.4M
FY2025
5-year range
$15.2M / $19.2M
FY2021-FY2025
Trend
-9.5%
vs FY2024
Sector context
#200 of 210
Health Care
What the data says
Among 210 Health Care companies, MARAVAI LIFESCIENCES HOLDINGS, INC. is in the bottom 5% for r&d expense. R&D Expense has fluctuated over the past 7 years, ranging from $4M in FY2019 to $19M in FY2024.
Based on SEC 10-K filings.
$17M in FY2025 with a 5-year CAGR of +13.3%.
Remained stable around $17M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -1.8%
- 5-Year CAGR
- +13.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 210This company $17.4M Sector average $644.1M
▼
-97.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +13.3%, indicating consistent growth.
- In FY2025, r&d expense decreased 9.5% year-over-year.
- Ranks #200 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.4M | -9.5% |
| FY2024 | $19.2M | +11.2% |
| FY2023 | $17.3M | -5.9% |
| FY2022 | $18.4M | +20.7% |
| FY2021 | $15.2M | +63.6% |
| FY2020 | $9.3M | +156.5% |
| FY2019 | $3.6M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026